StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a report released on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Lake Street Capital assumed coverage on shares of InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target on the stock.

InspireMD Trading Up 2.9 %

NYSE NSPR opened at $3.19 on Friday. The company’s fifty day simple moving average is $2.78 and its 200-day simple moving average is $2.74. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42. The stock has a market cap of $83.21 million, a P/E ratio of -4.25 and a beta of 1.00.

Hedge Funds Weigh In On InspireMD

Several institutional investors have recently modified their holdings of NSPR. Renaissance Technologies LLC bought a new position in InspireMD in the 4th quarter valued at about $27,000. Legato Capital Management LLC bought a new position in InspireMD in the 4th quarter valued at about $47,000. Schonfeld Strategic Advisors LLC grew its position in InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after buying an additional 18,233 shares in the last quarter. Northern Trust Corp grew its position in InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after buying an additional 24,452 shares in the last quarter. Finally, Essex Investment Management Co. LLC bought a new position in InspireMD in the 4th quarter valued at about $191,000. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.